Evotec and Debiopharm Group(TM) to Collaborate on Development of New Treatment for Cancer
April 02 2014 - 12:39AM
- Innovative partnership based on one of Evotec's Target
X projects
- Evotec and Debiopharm to share discovery and
development efforts
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) announced
today a research collaboration and licensing deal with Debiopharm
Group™ Lausanne, Switzerland. The objective of this collaboration
is to identify and develop novel compounds having the potential to
treat multiple forms of solid tumours and leukaemias with defined
genetic alterations. Discovery and pre-clinical development efforts
will be driven by Evotec, whilst Debiopharm will manage clinical
development. Evotec will receive R&D funding and high
double-digit total payments triggered by clinical, regulatory and
commercial milestones, plus royalties on sales of resulting
commercial products.
This programme is based on Evotec's drug discovery efforts to
investigate genetically altered targets whose 'driver' role in
several cancer types has been validated and on the shared objective
of identifying novel therapeutic agents in a variety of cancers,
including AML (Acute Myeloid Leukaemia), prostate cancer and
glioblastoma. Evotec is in the unique position of being able to
apply a broad range of highly sophisticated drug discovery tools
including state-of-the-art mass spectrometry and structure-based
drug design for rapid and efficient development of highly promising
lead series. Debiopharm is experienced in taking to maturity
promising early-stage biological or small molecule drug candidates
from pre-clinical to clinical development phase I, II and III,
including subsequent out-licensing to pharmaceutical partners for
sales and marketing.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec,
commented: "We are very excited about this innovative
collaboration structure between Debiopharm and Evotec. It combines
our proven discovery platform with Debiopharm's ability to advance
projects through clinical development in a highly efficient manner
while sharing risks and rewards of Evotec's Target X project. There
is compelling science around the target and we are confident that
we will be able to position highly competitive compounds in this
field that hold great potential for difficult to treat
cancers."
"This is a fine example of how drug discovery and development
will be in the future: a mixture of complementarities looking to
bring to a defined population of patients a drug that will change
the outcome of disease", added Andrés McAllister, Chief
Scientific Officer, Debiopharm International SA.
"Through this collaboration with Evotec, Debiopharm is
strengthening its position in early projects with a leader in the
drug discovery field", said Thierry Mauvernay, Delegate of
the Board of Debiopharm Group. "Furthermore, this R&D
program targeting cancers with known genetic alterations is a whole
part of our strategy for personalized medicines."
ABOUT DEBIOPHARM GROUP™
Debiopharm Group™ is a Swiss-based global biopharmaceutical
group of four companies active in drug development, GMP
manufacturing of proprietary drugs, diagnostics, and
investments.
Debiopharm International SA is focused on the development of
prescription drugs that target unmet medical needs. The company
in-licenses, develops and/or co-develops promising biological and
small molecule drug candidates for global registration. The
products are commercialized through out-licensing to pharmaceutical
partners to give access to the largest number of patients
worldwide. For more information about Debiopharm Group™, please
visit: www.debiopharm.com.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the
Company has existing development partnerships and product
candidates both in clinical and pre-clinical development. These
include partnerships with Boehringer Ingelheim, MedImmune and
Andromeda in the field of diabetes, with Janssen Pharmaceuticals in
the field of depression and with Roche in the field of Alzheimer's
disease. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-333 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel.: +41 (0)21 321 01 11
Additional Media Contacts
In London
Maitland
Brian Hudspith
bhudspith@maitland.co.uk
Tel.: +44 (0)20 7379 5151
In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
martina.schwarzkopf@russopartnersllc.com
Tel.: +1 212-845-4292
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024